Phase II study demonstrating failure of both a five-drug continuous-therapy regimen and a two-drug pulse-therapy regimen in the treatment of metastatic neuroblastoma: Southwest Oncology Group Study 822

Cancer Treat Rep. 1979 Aug;63(8):1383-4.

Abstract

Twenty-six children greater than 1 year of age with previously untreated stage IV neuroblastoma were randomized to receive either a five-drug regimen (prednisone, cyclophosphamide, actinomycin D, vincristine, and daunorubicin) or a two-drug regimen (cyclophosphamide and vincristine). Complete response rates were 6% and 9% for the five-drug and the two-drug regimens respectively. Partial response rates were 13% and 27% for the five-drug and the two-drug regimens respectively. The mean duration of the seven responses was 9 months, and all 26 patients had died within 2 years. Neither regimen was effective for long-term disease control in these children with neuroblastoma.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Cyclophosphamide / administration & dosage
  • Dactinomycin / administration & dosage
  • Daunorubicin / administration & dosage
  • Drug Evaluation
  • Drug Therapy, Combination
  • Humans
  • Infant
  • Neuroblastoma / drug therapy
  • Neuroblastoma / secondary*
  • Prednisone / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Antineoplastic Agents
  • Dactinomycin
  • Vincristine
  • Cyclophosphamide
  • Prednisone
  • Daunorubicin